Bedrijfsoverzicht
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical enterprise dedicated to the identification and development of pharmaceutical products through the utilization of its proprietary lipid nanocrystal (LNC) platform technology. This specific technology employs lipid nanocrystals to facilitate the delivery of small molecules and nucleic acids, aiming to enhance the efficacy and delivery mechanisms of therapeutic agents. The company operates within the Healthcare sector, specifically focusing on the Biotechnology industry, which implies a high-risk, high-reward environment centered on research, development, and the commercialization of novel medical treatments. With a market capitalization of $3.20M and an employee count of 2, the organization functions on a micro-cap scale, indicating a very early-stage or niche operation with limited operational footprint. The negligible revenue and minimal headcount suggest that the company is likely in a phase of intense research and development where capital is prioritized for product advancement rather than large-scale commercial sales or established market dominance.
Financiële gezondheid
The financial statements for Matinas BioPharma Holdings, Inc. reveal a company in a significant cash burn phase, reporting a net income of $-10,963,000 and an EBITDA of $-6,924,000 over the trailing twelve-month period. The substantial gap between the reported revenue status, which is not applicable due to lack of sales, and the deep net losses highlights a cost structure dominated by research expenditures and operational overhead rather than cost of goods sold. Free cash flow stands at $-3,339,625, which indicates a consistent outflow of capital that necessitates external financing or the depletion of existing cash reserves to sustain daily operations. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, reflecting the absence of traditional revenue streams that would allow for the generation of profit or operating leverage. Despite the negative earnings, the company maintains a cash position of $4.00M against total debt of $1.35M, resulting in a debt-to-equity ratio of 28.03 that suggests a capital structure heavily reliant on equity financing rather than creditor leverage. The balance sheet is currently supported by significant liquid assets, yet the negative profitability underscores the risk associated with the company's inability to cover its expenses from current operations. Liquidity is further supported by a current ratio of 2.79, indicating that the company holds 2.79 times more current assets than current liabilities, which provides a buffer against short-term obligations despite the lack of operating income. However, the return on equity is -166.6% and the return on assets is -43.8%, metrics that reveal that management has not yet generated positive returns on the capital invested in the business.
Waarderingsbeoordeling
Valuation metrics for Matinas BioPharma Holdings, Inc. are distorted by the lack of earnings, resulting in a P/E Ratio (TTM) that is not applicable and a forward P/E of -0.17. The negative forward P/E ratio implies that the market is pricing in future earnings that are not yet realized, a common characteristic of clinical-stage biotechnology firms that have not reached commercial viability. The price-to-book ratio is calculated at 0.46, indicating that the company's current market value trades at less than half of its book value, suggesting the market does not assign a premium to its intangible assets or future potential. Alternative valuation measures such as the price-to-sales ratio are not applicable due to the absence of revenue, while the EV/EBITDA stands at -0.08, further emphasizing the company's pre-profitability status. The stock has experienced significant volatility, trading between a 52-week high of $3.09 and a 52-week low of $0.48. When analyzing the price range, the current valuation sits below the recent highs, reflecting the high-risk nature of the asset class. The beta value is 1.40, which indicates that the stock's price volatility is 40% higher than that of the broader market, exposing investors to greater fluctuations during periods of market stress.
Growth & Income
There is no applicable revenue growth or earnings growth rate available for Matinas BioPharma Holdings, Inc., as the company has not yet generated commercial revenue to calculate year-over-year expansion. Consequently, it is impossible to determine whether earnings are growing faster or slower than revenue, as both are currently non-existent in a traditional sense. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the firm reinvests all available capital and potential earnings into its research and development efforts rather than distributing income to shareholders. This reinvestment strategy is typical for clinical-stage biotechnology companies that must prioritize product development over income distribution to achieve regulatory approval and market entry. The overall growth and income profile is characterized by a complete absence of current financial returns, relying entirely on the potential future success of its lipid nanocrystal platform technology to generate value.